Equities research analysts forecast that Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) will report ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Momenta Pharmaceuticals’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.81). Momenta Pharmaceuticals posted earnings per share of ($0.07) during the same quarter last year, which would suggest a negative year-over-year growth rate of 742.9%. The business is expected to announce its next earnings report on Friday, February 28th.
According to Zacks, analysts expect that Momenta Pharmaceuticals will report full-year earnings of ($2.58) per share for the current year, with EPS estimates ranging from ($2.88) to ($2.10). For the next year, analysts expect that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.51) to ($1.74). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Momenta Pharmaceuticals.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.09). The firm had revenue of $6.40 million for the quarter, compared to the consensus estimate of $5.24 million. Momenta Pharmaceuticals had a negative return on equity of 59.82% and a negative net margin of 361.66%. The business’s revenue was down 57.0% on a year-over-year basis. During the same period last year, the company posted ($0.65) EPS.
In related news, CEO Craig A. Wheeler sold 2,601 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.16, for a total transaction of $42,032.16. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Anthony M. Manning sold 6,365 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $13.83, for a total value of $88,027.95. Following the sale, the insider now directly owns 20,603 shares in the company, valued at approximately $284,939.49. The disclosure for this sale can be found here. In the last three months, insiders sold 177,262 shares of company stock valued at $2,862,158. 3.40% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Momenta Pharmaceuticals by 2.9% during the second quarter. BlackRock Inc. now owns 15,606,505 shares of the biotechnology company’s stock worth $194,302,000 after purchasing an additional 438,679 shares during the last quarter. Vanguard Group Inc. boosted its position in Momenta Pharmaceuticals by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 10,436,152 shares of the biotechnology company’s stock worth $129,931,000 after buying an additional 129,762 shares during the period. Perceptive Advisors LLC boosted its position in Momenta Pharmaceuticals by 1.0% during the 2nd quarter. Perceptive Advisors LLC now owns 2,905,000 shares of the biotechnology company’s stock worth $36,167,000 after buying an additional 30,000 shares during the period. Point72 Asset Management L.P. grew its holdings in Momenta Pharmaceuticals by 1,147.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,581,229 shares of the biotechnology company’s stock worth $33,453,000 after acquiring an additional 2,374,229 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Momenta Pharmaceuticals by 0.9% during the 2nd quarter. Northern Trust Corp now owns 1,275,473 shares of the biotechnology company’s stock worth $15,879,000 after acquiring an additional 11,012 shares during the last quarter. Hedge funds and other institutional investors own 97.04% of the company’s stock.
MNTA traded up $1.17 during trading on Friday, hitting $18.02. 1,063,160 shares of the stock traded hands, compared to its average volume of 539,580. Momenta Pharmaceuticals has a twelve month low of $9.51 and a twelve month high of $18.06. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -8.88 and a beta of 2.07. The business has a 50 day moving average price of $15.76 and a 200 day moving average price of $13.11.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Read More: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.